Vertex Pharmaceuticals

Vertex Pharmaceuticals is a biotechnology company with activities spanning the length of the pharmaceutical product pipeline, from target identification through to clinical trials and marketing. Most of its activity has been in collaboration with much larger pharmaceutical firms, though some of its recent work has been done independently. Vertex was founded in 1989 by Joshua Boger, credited as being one of the main reasons for the company's early success due to his strong fund-raising and company cash flow management. Vertex was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. Vertex went about understanding a disease and then tried to develop a process to cure it. In 2004, its product pipeline focused on viral infections, inflammatory and autoimmune disorders, and cancer. Its capital investments include a headquarters in Cambridge, Massachusetts, and two research facilities, in San Diego, California, and Oxford, England. The company's beginnings were profiled by Barry Werth in the 1994 book "The Billion-Dollar Molecule".

Source: Wikipedia

Campaign Finance

Information

Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:

  • contributions under $200 are not reported, and so are not included in totals.
  • only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
  • contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
  • corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
  • organization totals include known subsidiaries of the organization.

For more information, please see our campaign finance methodology page. Lobbyist bundling data is described on our lobbyist bundling methodology page.

Latest FEC Data

covers through committee's June 30, 2012 filing.
Download all contributions to Vertex Pharmaceuticals

  • Summary

    overview of the committee's finances
    Total Raised:
    $47,326
    Total Spent:
    $44,974
    Cash on Hand:
    $12,998
    Debts:
    $0

Standardized Donation Information

covers through 2011. may lag behind FEC section above, as donors and industries are identified by hand.

  • Top Recipients

    Employee Color Block
    Individuals
    PAC Color Block
    PAC
    Includes contributions from the organization’s employees, their family members, and its political action committee.

  • Republicans vs. Democrats

    in dollars

  • State vs. Federal

    in dollars

  • Top PAC Recipients

    Employee Color Block
    Individuals
    PAC Color Block
    PAC
    Includes contributions from the organization’s employees, their family members, and its political action committee.
View all campaign finance data for Vertex Pharmaceuticals Sources: OpenSecrets.org

Lobbying

$1,270,000 Spent
Information

Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.

For more information, please see our lobbying methodology page.

covers through Q3, 2011

Lobbying On Behalf of Vertex Pharmaceuticals

View all lobbying data for Vertex Pharmaceuticals Sources: OpenSecrets.org

Regulations

3 Mentions; 1 Submissions
Information

All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.

Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.

Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.

Regulations and public comments can be downloaded in bulk here.

updated from Regulations.gov on September 27, 2011

The tables show occurrences of "Vertex Pharmaceuticals" in public comments on proposed federal regulations.

  • Documents Submitted by the Organization
    • Submissions
    • Agency
    • Docket
    • Date
    • Toggle 1 FDA International Conference on Harmonisation; Draft Guidance on Q11 Development and Manufacture of Drug Substances; Availability 2011
  • Mentions in Document Text
    • Mentions
    • Agency
    • Docket
    • Date
    • Toggle 2 FDA Advisory Committee, Workshops, and Conferences Notices Various Meeting Notices (eg., Task Force Meeting, etc.) 2011
    • Toggle 1 FDA International Conference on Harmonisation; Draft Guidance on Q11 Development and Manufacture of Drug Substances; Availability 2011
    • Toggle 1 FDA Conduct a Postmarketing Clinical Trial Involving the Drug Industry, NIH, The New York DOCS, FDA, and the Participation of the New York State Prisoners Who Suffer From Hep C 2011